After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA methylation regulate gene expression in ...

Dassault Systèmes agreed to buy Arisglobal for up to $2 billion as it strengthens its position in the life sciences sector, advancing its ambition to create a unified AI intelligence platform for the ...

Once again, Arrowhead Pharmaceuticals Inc.’s Redemplo (plozasiran) is hot on the heels of Ionis Pharmaceuticals Inc.’s ...

Scientists in Europe have added their voices to the many thousands of objections made against proposed changes to the oversight of U.S. federal research grants, under which political appointees and ...

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s Committee for Medicinal Products for Human ...

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric ...

Investigators at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have demonstrated that in the ...

Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Axiom, Eisai, Immutep, Innocare, Kelun-Biotech, Medinno, Merck ...

On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Cellution, Dimerix, Elutia, IPG, Jasper, Kira, Lumibird, Medtronic ...

Immix Biopharma Inc.’s shares (NASDAQ:IMMX) sank 14% to $8.80 on July 20 after investors learned that a man named Richard Graydon, who served as its chief medical officer, was in fact a 20-year ...